Saratani

Researchers reported at Digestive Disease Week (DDW) 2026 that older mice given fecal microbiota transplants made from their own preserved, younger-age stool samples showed less liver inflammation and injury—and none developed liver cancer in the experiment.

30 Mwezi wa nne, 2026 Imeripotiwa na AI Imethibitishwa ukweli

Researchers from the University of Geneva and Lausanne University Hospital report they have visualized, in three dimensions and under near-native conditions, how cytotoxic T cells organize their killing machinery at the immune synapse. The work, published in Cell Reports, applies cryo-expansion microscopy to human T cells and to tumor tissue samples, providing nanoscale views intended to support immunology and cancer research.

Tekur Anbesa Specialized Hospital in Addis Ababa has inaugurated a modern 27-bed cancer treatment center built at a cost of 6 million birr. The facility aims to enhance the quality of cancer and palliative care services, officials stated. Plans for prompt expansion of similar centers were announced.

15 Mwezi wa nne, 2026 Imeripotiwa na AI

Researchers at Fred Hutch Cancer Center have created human-like monoclonal antibodies that prevent Epstein-Barr virus (EBV) from infecting immune cells. Using mice engineered with human antibody genes, the team identified antibodies targeting viral proteins gp350 and gp42, with one fully blocking infection in lab models. The findings, published in Cell Reports Medicine, could lead to therapies for transplant patients at risk of EBV-related complications.

Scientists at McMaster University and the Hospital for Sick Children in Canada have discovered that oligodendrocytes, cells typically supporting nerve function, aid the growth of glioblastoma by sending signals to tumor cells. Blocking this communication slowed tumor progression in lab models. The findings suggest an existing HIV drug, Maraviroc, could be repurposed for treatment.

5 Mwezi wa nne, 2026 Imeripotiwa na AI Imethibitishwa ukweli

Researchers in Brazil report that an artificial-saliva formulation made with a lab-modified sugarcane protein, CaneCPI-5 (also written CANECPI-5), can bind to tooth enamel and help reduce bacterial activity and mineral loss in laboratory experiments designed to model the severe dental risks faced by head and neck cancer patients after radiotherapy. The work, published in the Journal of Dentistry, found the formulation performed best when combined with fluoride and xylitol.